Grifols Egypt is committed to developing the plasma medicine industry and achieving self-sufficiency in these medicines of high importance to the health system in Egypt.
The first shipment of the human albumin medicine, which was manufactured from Egyptian plasma in Grifols plant in Spain, arrived in Cairo Thursday.
The Cabinet approved Thursday a contract between the Ministry of Health and Population, and the Spanish company.
Egypt’s Ministry of Health said, Friday that the Presidential initiative for manufacturing and achieving self-sufficiency of plasma derivatives is progressing steadily towards achieving its goals.
Other plasma donation venues include the regional blood transfusion centers in Cairo’s Dar El-Salam and Abbasiya districts, Alexandria, Gharbiya and Minya, the spokesman added.
Donation is made at six centers located across five governorates, and consisting of a total of 99 plasma separation devices.
The Ministry of Health announced it has received 1,320 plasma so far since the a national plasma donation project was launched last month.
It also includes a set of general provisions about the donation process and the tests needed before donating or using blood plasma.
More than 300 plasma donors were registered so far since a national project to achieve self-sufficiency of plasma derivatives launched earlier this month.
Egypt has launched the national plasma donation project as part of a presidential initiative for the production and self-sufficiency of plasma derivatives.
Now, Egypt imports its needs of plasma derivatives to treat burn injuries, cancer, haemophilia, and diseases of the liver, kidneys, and immunity.
The Parliament is expected to discuss in its next plenary session a draft law submitted by the government to regulate blood operations and plasma collection.
The President ordered the government to complete all scientific and technical aspects of the project in accordance with the highest and international standards.
Private hospitals and laboratories are not authorized to separate plasma of those who recovered from COVID-19 to be injected into infected patients.